Victory Capital Management Inc. Sells 171 Shares of Penumbra, Inc. (NYSE:PEN)

Victory Capital Management Inc. lessened its stake in Penumbra, Inc. (NYSE:PEN) by 2.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 7,165 shares of the company’s stock after selling 171 shares during the period. Victory Capital Management Inc.’s holdings in Penumbra were worth $1,702,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. bought a new stake in shares of Penumbra in the 4th quarter valued at about $573,000. State Street Corp boosted its position in shares of Penumbra by 0.3% during the 3rd quarter. State Street Corp now owns 1,236,671 shares of the company’s stock valued at $240,298,000 after purchasing an additional 3,863 shares in the last quarter. E. Ohman J or Asset Management AB boosted its position in shares of Penumbra by 10.4% during the 4th quarter. E. Ohman J or Asset Management AB now owns 21,312 shares of the company’s stock valued at $5,061,000 after purchasing an additional 2,000 shares in the last quarter. LMR Partners LLP bought a new stake in shares of Penumbra during the 3rd quarter valued at about $2,330,000. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Penumbra by 1.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 271,574 shares of the company’s stock valued at $64,493,000 after purchasing an additional 3,807 shares in the last quarter. Institutional investors own 88.88% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on PEN shares. Wells Fargo & Company upped their target price on Penumbra from $275.00 to $305.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Canaccord Genuity Group upped their target price on Penumbra from $323.00 to $340.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. UBS Group upped their target price on Penumbra from $305.00 to $320.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Citigroup upped their target price on Penumbra from $220.00 to $245.00 and gave the company a “neutral” rating in a research report on Wednesday, December 11th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Penumbra in a research note on Wednesday, February 19th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $294.47.

Penumbra Trading Down 0.2 %

Shares of PEN stock opened at $275.40 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01. Penumbra, Inc. has a 52-week low of $148.00 and a 52-week high of $310.00. The company has a market capitalization of $10.61 billion, a PE ratio of 810.01, a price-to-earnings-growth ratio of 2.83 and a beta of 0.51. The business’s fifty day moving average is $271.17 and its 200 day moving average is $238.92.

Penumbra (NYSE:PEN) last issued its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.09. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The company had revenue of $315.52 million for the quarter, compared to the consensus estimate of $311.63 million. On average, equities research analysts anticipate that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Insider Buying and Selling at Penumbra

In other Penumbra news, EVP Johanna Roberts sold 600 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $287.43, for a total transaction of $172,458.00. Following the sale, the executive vice president now owns 66,539 shares in the company, valued at $19,125,304.77. This trade represents a 0.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Maggie Yuen sold 2,000 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $286.00, for a total value of $572,000.00. Following the sale, the chief financial officer now owns 15,243 shares in the company, valued at $4,359,498. The trade was a 11.60 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 79,918 shares of company stock worth $22,054,293 over the last 90 days. Corporate insiders own 5.00% of the company’s stock.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.